InvestorsHub Logo

eightisenough

11/10/19 10:17 AM

#224014 RE: Atom0aks #224011

Atom--NLA, AHA & ADA endorsed Vascepa!! How could you say "I currently predict that the vote could go either way"?

VuBru

11/10/19 10:45 AM

#224025 RE: Atom0aks #224011

Atom - My bet is that they get exactly the population that R-It included:
1) Existing CVD, on statins, with TGs>150 (or 135)
2) T2DM, on statins, with CV risk, and TGs>150 (or 135)

There are no data to support a broad primary prevention label (R-It did not include any non-diabetic primary prevention), so this would be highly unlikely.

A label less than R-It ignores a solid statistical argument for including both, and in the end, I think the scientists and statisticians will agree on this.

sharinky

11/10/19 10:52 AM

#224029 RE: Atom0aks #224011

Why would you compare the diabetes population of one trial with the non-diabetic population of another trial?

dmlcento

11/10/19 11:55 AM

#224069 RE: Atom0aks #224011